13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001778253
Total reported value
$928.2M
$928.2M
147 檔
27.1%
At the close of Q4 2024, Ikarian Capital, LLC disclosed equity holdings valued at approximately $928.2M, spread across 147 reported holdings.
Ikarian Capital, LLC executed strategic sector rebalancing during Q4 2024, establishing 47 new positions while fully exiting 21 holdings and trimming 64 positions.
In terms of portfolio concentration, the top 5 core holdings (including XBI, TSN, TARS) accounted for 27.1% of total reported equity market value during Q4 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 17.76% | -3.19% | +190.00% | |
| 2 | TSN | Tyson Foods Inc-cl A | Stock-Consumer Staples | 4.92% | — | — | |
| 3 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 4.58% | +0.03% | -41.02% | |
| 4 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 3.59% | — | +20.97% | |
| 5 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 3.42% | -0.86% | +220.61% | |
| 6 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.70% | — | +13.63% | |
| 7 | AMGN | Amgen Inc | Stock-Healthcare | 2.62% | — | -53.55% | |
| 8 | INSM | Insmed Inc | Stock-Healthcare | 2.53% | -0.06% | EXIT | |
| 9 | 2655787D | Blueprint Medicines CORP | Stock-Other | 2.01% | — | +99.26% | |
| 10 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 1.98% | — | — | |
| 11 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.90% | — | +112.43% | |
| 12 | FBRX | Forte Biosciences Inc | Stock-Other | 1.88% | -0.20% | — | |
| 13 | PPC | Pilgrim's Pride CORP | Stock-Consumer Staples | 1.85% | — | — | |
| 14 | NMRA | Neumora Therapeutics Inc | Stock-Other | 1.80% | +0.03% | +56.25% | |
| 15 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.68% | +0.84% | NEW | |
| 16 | VIR | Vir Biotechnology Inc | Stock-Other | 1.62% | -0.21% | EXIT | |
| 17 | CAPR | Capricor Therapeutics Inc | Stock-Other | 1.24% | +0.31% | -26.54% | |
| 18 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.21% | +0.42% | -21.02% | |
| 19 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 1.19% | — | — | |
| 20 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.15% | — | — | |
| 21 | RCUS | Arcus Biosciences Inc | Stock-Other | 1.05% | +1.68% | NEW | |
| 22 | CALM | Cal-maine Foods Inc | Stock-Consumer Staples | 1.05% | — | — | |
| 23 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.05% | — | +146.60% | |
| 24 | DNA | Ginkgo Bioworks Holdings Inc | Stock-Other | 1.03% | — | — | |
| 25 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.02% | -0.22% | -0.01% | |
| 26 | IMVT | Immunovant Inc | Stock-Other | 1.01% | — | -39.88% | |
| 27 | ANAB | Anaptysbio Inc | Stock-Other | 1.01% | — | -25.65% | |
| 28 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 0.99% | — | -16.32% | |
| 29 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.98% | -0.50% | -0.01% | |
| 30 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.96% | -6.65% | EXIT | |
| 31 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 0.91% | — | +474.62% | |
| 32 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.90% | — | +111.13% | |
| 33 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.89% | +0.36% | -46.72% | |
| 34 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.89% | — | -6.65% | |
| 35 | KOD | Kodiak Sciences Inc | Stock-Other | 0.78% | +1.13% | +20.89% | |
| 36 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.75% | — | +0.05% | |
| 37 | ONC | Beone Medicines Ltd-adr | Stock-Other | 0.75% | — | -74.74% | |
| 38 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 0.75% | -0.32% | — | |
| 39 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.71% | +0.90% | -66.37% | |
| 40 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.63% | — | — | |
| 41 | ACOG | Alpha Cognition Inc | Stock-Other | 0.61% | +0.18% | — | |
| 42 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.59% | — | -26.90% | |
| 43 | RZLT | Rezolute Inc | Stock-Other | 0.57% | +0.52% | -3.38% | |
| 44 | MRNA | Moderna Inc | Stock-Healthcare | 0.57% | +3.02% | NEW | |
| 45 | EOLS | Evolus Inc | Stock-Other | 0.56% | — | +44.52% | |
| 46 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.56% | — | +84.66% | |
| 47 | NUVL | Nuvalent Inc-a | Stock-Other | 0.56% | -0.20% | EXIT | |
| 48 | JANX | Janux Therapeutics Inc | Stock-Other | 0.54% | — | -79.55% | |
| 49 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.51% | — | — | |
| 50 | HELP | Cybin Inc | Stock-Other | 0.48% | +0.04% | +8.16% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | +10.9% | +190.00% | Add |
| 2 | TSN | Tyson Foods Inc-cl A | +4.9% | NEW | New buy |
| 3 | BBIO | Bridgebio Pharma Inc | +2.4% | +220.61% | Add |
| 4 | SRRK | Scholar Rock Holding CORP | +2.3% | +13.63% | Add |
| 5 | RNAGBP | Avidity Biosciences Inc | +2% | NEW | New buy |
| 6 | FBRX | Forte Biosciences Inc | +1.9% | NEW | New buy |
| 7 | PPC | Pilgrim's Pride CORP | +1.9% | NEW | New buy |
| 8 | VIR | Vir Biotechnology Inc | +1.6% | NEW | New buy |
| 9 | TGTX | Tg Therapeutics Inc | +1.2% | NEW | New buy |
| 10 | AXSM | Axsome Therapeutics Inc | +1.2% | NEW | New buy |
| 11 | CALM | Cal-maine Foods Inc | +1.1% | NEW | New buy |
| 12 | DNA | Ginkgo Bioworks Holdings Inc | +1% | NEW | New buy |
| 13 | SRPT | Sarepta Therapeutics Inc | +1% | +112.43% | Add |
| 14 | INSM | Insmed Inc | +1% | +74.25% | Add |
| 15 | 2655787D | Blueprint Medicines CORP | +0.9% | +99.26% | Add |
| 16 | CRVS | Corvus Pharmaceuticals Inc | +0.8% | +474.62% | Add |
| 17 | DRUG | Bright Minds Biosciences Inc | +0.8% | NEW | New buy |
| 18 | ELDN | Eledon Pharmaceuticals Inc | +0.6% | NEW | New buy |
| 19 | KOD | Kodiak Sciences Inc | +0.6% | +20.89% | Add |
| 20 | ACOG | Alpha Cognition Inc | +0.6% | NEW | New buy |
| 21 | MRNA | Moderna Inc | +0.6% | NEW | New buy |
| 22 | CRNX | Crinetics Pharmaceuticals In | +0.6% | +20.97% | Add |
| 23 | VRNA | Verona Pharma PLC - Adr | +0.5% | NEW | New buy |
| 24 | ARCT | Arcturus Therapeutics Holdin | +0.5% | NEW | New buy |
| 25 | PTGX | Protagonist Therapeutics Inc | +0.4% | NEW | New buy |
| 26 | GPCR | Structure Therapeutics Inc | +0.4% | +146.60% | Add |
| 27 | ALGS | Aligos Therapeutics Inc | +0.4% | NEW | New buy |
| 28 | NMRA | Neumora Therapeutics Inc | +0.3% | +56.25% | Add |
| 29 | ZVRA | Zevra Therapeutics Inc | +0.3% | NEW | New buy |
| 30 | NVAX | Novavax Inc | +0.3% | NEW | New buy |
| 31 | ALT | Altimmune Inc | +0.3% | NEW | New buy |
| 32 | TEVA | Teva Pharmaceutical-sp Adr | +0.3% | NEW | New buy |
| 33 | OKUR | Onkure Therapeutics Inc-a | +0.3% | NEW | New buy |
| 34 | VTYXUSD | Ventyx Biosciences Inc | +0.3% | +467.15% | Add |
| 35 | HROW | Harrow Inc | +0.3% | NEW | New buy |
| 36 | CRDF | Cardiff Oncology Inc | +0.3% | NEW | New buy |
| 37 | MLYS | Mineralys Therapeutics Inc | +0.3% | +84.66% | Add |
| 38 | SGMOQ | Sangamo Therapeutics Inc | +0.3% | NEW | New buy |
| 39 | ALEC | Alector Inc | +0.2% | NEW | New buy |
| 40 | DYN | Dyne Therapeutics Inc | +0.2% | +111.13% | Add |
| 41 | TARA | Protara Therapeutic Inc | +0.2% | +125.09% | Add |
| 42 | CDTX | Cidara Therapeutics Inc | +0.2% | NEW | New buy |
| 43 | VTLUSD | Immunic Inc | +0.2% | +355.92% | Add |
| 44 | TRVI | Trevi Therapeutics Inc | +0.2% | NEW | New buy |
| 45 | LXRX | Lexicon Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 46 | BMEA | Biomea Fusion Inc | +0.2% | +713.40% | Add |
| 47 | ✓ | Third Harmonic Bio Inc | +0.1% | NEW | New buy |
| 48 | LXEO | Lexeo Therapeutics Inc | +0.1% | +94.12% | Add |
| 49 | TRAW | Traws Pharma Inc | +0.1% | NEW | New buy |
| 50 | ACRS | Aclaris Therapeutics Inc | +0.1% | NEW | New buy |
According to official SEC Form 13F filings, Ikarian Capital, LLC reported a total U.S. public equity portfolio value of $928.2M across 147 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
TSN
市值: $36.2M
Top Position Liquidated / Trimmed
VRTX
前期市值: $93.0M
During Q4 2024, Ikarian Capital, LLC's top holdings by market value included XBI (17.8%)、TSN (4.9%)、TARS (4.6%). The largest single position, XBI, represented 17.8% of total portfolio value.
In Q4 2024, Ikarian Capital, LLC made 166 total portfolio adjustments, initiating 47 new buys, adding to 34 positions, trimming 64 holdings, and fully liquidating 21 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.